Compare MyFirstApp Sweden AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 152 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.72
97.69%
-10.49
Revenue and Profits:
Net Sales:
28 Million
(Quarterly Results - Mar 2026)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
13.24%
0%
13.24%
6 Months
-7.14%
0%
-7.14%
1 Year
140.74%
0%
140.74%
2 Years
49.77%
0%
49.77%
3 Years
3216.33%
0%
3216.33%
4 Years
1592.71%
0%
1592.71%
5 Years
324.28%
0%
324.28%
MyFirstApp Sweden AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
101.85%
EBIT Growth (5y)
13.87%
EBIT to Interest (avg)
-6.73
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
-0.51
Tax Ratio
2.10%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
15.89%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-8.82
EV to EBIT
-108.62
EV to EBITDA
138.03
EV to Capital Employed
-33.97
EV to Sales
4.18
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Bearish
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
27.50
0.10
27,400.00%
Operating Profit (PBDIT) excl Other Income
3.00
-0.20
1,600.00%
Interest
1.40
0.40
250.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-1.70
-1.20
-41.67%
Operating Profit Margin (Excl OI)
49.70%
-12,251.50%
1,230.12%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 27,400.00% vs -80.00% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is -41.67% vs 40.00% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
122.50
2.50
4,800.00%
Operating Profit (PBDIT) excl Other Income
5.10
-0.40
1,375.00%
Interest
3.20
1.20
166.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-5.90
-11.70
49.57%
Operating Profit Margin (Excl OI)
-13.30%
-1,724.70%
171.14%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 4,800.00% vs 19.05% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 49.57% vs -178.57% in Dec 2024
About MyFirstApp Sweden AB 
MyFirstApp Sweden AB
Pharmaceuticals & Biotechnology
ObsteCare AB is a Sweden-based provider of solutions within area of childbirth care. The Company is a developer of Amniotic Fluid Lactate (AFL) method, which aims to measure lactic acid content in the fetal water. Samples of amniotic fluid are collected and analyzed for the concentration of lactate. The lactate level is automatically presented in the partogram. By combining the result with the development of cervix dilatation a thorough understanding of the delivery status is obtained. The fluid is collected with a standard syringe. The fluid is delivered into the single use measuring probe on the measuring unit and the measurement starts automatically. The method is used by clinics primarily in the Nordic countries, the United Kingdom and the Baltic States.
Company Coordinates 
Company Details
Fogdevreten 2 , SOLNA None : 171 65
Registrar Details






